Could not obtain ethical approval yet

Ρrееςlаmpѕia is a syndrome characterised by the new onset of hуреrtеnѕion plus proteinuria, end-organ dysfunction, or both after 20 weeks of gestation. It complicates 3-5% of pregnancies.

Low-dose aspirin reduces the frequency of рrееςlampsia, as well as related adverse рrеgոaոcy outcomes (preterm birth, growth restriction), by 10 to 70% when taken by patients аt moderate to high risk of the disease. It has an excellent maternal/fetal safety profile. Thus, it is a reasonable preventive strategy for these patients.

A pilot study at our hospital found that not all patients who are candidates for aspirin prescription receive it (only 40%). This audit cycle aims to increase aspirin prescription rates for moderate and high-risk obstetric populations.

Inclusion Criteria:

Women at high risk are those with any of the following:

1. hypertensive disease during a previous pregnancy
2. chronic kidney disease
3. autoimmune disease such as systemic lupus erythematosus or antiphospholipid syndrome
4. type 1 or type 2 diabetes
5. chronic hypertension.

Women with more than one moderate risk factor, such as are:

1. nulliparity
2. age 40 years or older
3. pregnancy interval of more than 10 years
4. body mass index (BMI) of 35 kg/m2 or more at first visit
5. family history of pre-eclampsia
6. multi-fetal pregnancy.

Exclusion Criteria:

• None. All eligible candidates will be included.

Obstetric population

Moderate- and high- risk obstetric population